Neuroticism but not omega-3 fatty acid levels correlate with early responsiveness to escitalopram

Annals of Clinical Psychiatry

Volumn 22, Issue 3, 2010, Pages 157-163

  Fiedorowicz, Jess G ^a,b   Hale, Nancy ^a   Spector, Arthur A ^a   Coryell, William H ^a  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

Antidepressant; Anxiety; Major depression; Neuroticism; Omega 3 fatty acids

Indexed keywords

ARACHIDONIC ACID; DOCOSAHEXAENOIC ACID; ESCITALOPRAM; ICOSAPENTAENOIC ACID; OMEGA 3 FATTY ACID; OMEGA 6 FATTY ACID; SEROTONIN UPTAKE INHIBITOR; ANTIDEPRESSANT AGENT; CITALOPRAM;

ADULT; ANXIETY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CORRELATION ANALYSIS; ERYTHROCYTE; FEMALE; HUMAN; LIPID COMPOSITION; MAJOR DEPRESSION; MALE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; NEUROSIS; OPEN STUDY; PERSONALITY TEST; PRIORITY JOURNAL; PROGNOSIS; REVISED NEO PERSONALITY INVENTORY; TREATMENT DURATION; TREATMENT RESPONSE; ANXIETY DISORDER; BLOOD; CHARACTER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; METABOLISM; MIDDLE AGED; PROSPECTIVE STUDY; PSYCHOLOGICAL ASPECT; PSYCHOMETRY; STATISTICS; TREATMENT OUTCOME;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANXIETY DISORDERS; CHARACTER; CITALOPRAM; DEPRESSIVE DISORDER, MAJOR; ERYTHROCYTES; FATTY ACIDS, OMEGA-3; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROTIC DISORDERS; PERSONALITY INVENTORY; PROGNOSIS; PROSPECTIVE STUDIES; PSYCHOMETRICS; TREATMENT OUTCOME;

EID: 79952110266     PISSN: 10401237     EISSN: 15473325     Source Type: Journal    
DOI: None     Document Type: Article

References (61)

1. Hibbeln JR. Fish consumption and major depression. Lancet. 1998;351:1213.
2. Tanskanen A, Hibbeln JR, Tuomilehto J, et al. Fish consumption and depressive symptoms in the general population in Finland. Psychiatr Serv. 2001;52:529-531. (Pubitemid 32275317)
3. Peet M, Murphy B, Shay J, et al. Depletion of omega-3 fatty acid levels in red blood cell membranes of depressive patients. Biol Psychiatry. 1998;43:315-319. (Pubitemid 28137622)
4. Maes M, Christophe A, Delanghe J, et al. Lowered omega3 polyunsaturated fatty acids in serum phospholipids and cholesteryl esters of depressed patients. Psychiatry Res. 1999;85:275-291. (Pubitemid 29202389)
5. Silvers KM, Scott KM. Fish consumption and selfreported physical and mental health status. Public Health Nutr. 2002;5:427-431. (Pubitemid 34614910)
6. Adams PB, Lawson S, Sanigorski A, et al. Arachidonic acid to eicosapentaenoic acid ratio in blood correlates positively with clinical symptoms of depression. Lipids. 1996;31(suppl):S157-S161.
7. Edwards R, Peet M, Shay J, et al. Omega-3 polyunsaturated fatty acid levels in the diet and in red blood cell membranes of depressed patients. J Affect Disord. 1998;48:149.
8. Hakkarainen R, Partonen T, Haukka J, et al. Is low dietary intake of omega-3 fatty acids associated with depression? Am J Psychiatry. 2004;161:567-569. (Pubitemid 38326115)
9. Peet M, Horrobin DF. A dose-ranging study of the effects of ethyl-eicosapentaenoate in patients with ongoing depression despite apparently adequate treatment with standard drugs. Arch Gen Psychiatry. 2002;59: 913-919
10. Nemets B, Stahl Z, Belmaker RH. Addition of omega-3 fatty acid to maintenance medication treatment for recurrent unipolar depressive disorder. Am J Psychiatry. 2002;159:477-479. (Pubitemid 34184747)
11. Su KP, Huang SY, Chiu CC, et al. Omega-3 fatty acids in major depressive disorder. A preliminary doubleblind, placebo-controlled trial. Eur Neuropsychopharmacol. 2003;13:267-271. (Pubitemid 36904053)
12. Jazayeri S, Tehrani-Doost M, Keshavarz SA, et al. Comparison of therapeutic effects of omega-3 fatty acid eicosapentaenoic acid and fluoxetine, separately and in combination, in major depressive disorder. Aust N Z J Psychiatry. 2008;42:192-198. (Pubitemid 351234188)
13. Nemets H, Nemets B, Apter A, et al. Omega-3 treatment of childhood depression: a controlled, doubleblind pilot study. Am J Psychiatry. 2006;163:1098-1100. (Pubitemid 44464498)
14. Grenyer BF, Crowe T, Meyer B, et al. Fish oil supplementation in the treatment of major depression: a randomised double-blind placebo-controlled trial. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31:1393-1396. (Pubitemid 47304478)
15. Marangell LB, Martinez JM, Zboyan HA, et al. A double-blind, placebo-controlled study of the omega-3 fatty acid docosahexaenoic acid in the treatment of major depression. Am J Psychiatry. 2003;160:996-998. (Pubitemid 41079588)
16. Silvers KM, Woolley CC, Hamilton FC, et al. Randomised double-blind placebo-controlled trial of fish oil in the treatment of depression. Prostaglandins Leukot Essent Fatty Acids. 2005;72:211-218. (Pubitemid 40139086)
17. Rogers PJ, Appleton KM, Kessler D, et al. No effect of n-3 long-chain polyunsaturated fatty acid (EPA and DHA) supplementation on depressed mood and cognitive function: a randomised controlled trial. Br J Nutr. 2008;99:421-431.
18. Freeman MP, Hibbeln JR, Wisner KL, et al. Omega-3 fatty acids: evidence basis for treatment and future research in psychiatry. J Clin Psychiatry. 2006;67: 1954-1967. (Pubitemid 46048194)
19. Lin PY, Su KP. A meta-analytic review of double- blind, placebo-controlled trials of antidepressant efficacy of omega-3 fatty acids. J Clin Psychiatry. 2007;68:1056-1061. (Pubitemid 47340326)
20. Appleton KM, Hayward RC, Gunnell D, et al. Effects of n-3 long-chain polyunsaturated fatty acids on depressed mood: systematic review of published trials. Am J Clin Nutr. 2006;84:1308-1316. (Pubitemid 44912811)
21. Tanum L, Malt UF. Personality traits predict treatment outcome with an antidepressant in patients with functional gastrointestinal disorder. Scand J Gastroenterol. 2000;35:935-941.
22. Berlanga C, Heinze G, Torres M, et al. Personality and clinical predictors of recurrence of depression. Psychiatr Serv. 1999;50:376-380. (Pubitemid 29122567)
23. Davidson J, Lipper S, Pelton S, et al. The response of depressed inpatients to isocarboxazid. J Clin Psychopharmacol. 1988;8:100-107.
24. Boyce P, Parker G. Neuroticism as a predictor of outcome in depression. J Nerv Ment Dis. 1985;173:685-688. (Pubitemid 16191984)
25. Petersen T, Papakostas GI, Bottonari K, et al. NEOFFI factor scores as predictors of clinical response to fluoxetine in depressed outpatients. Psychiatry Res. 2002;109:9-16. (Pubitemid 34159305)
26. Joyce PR, Paykel ES. Predictors of drug response in depression. Arch Gen Psychiatry. 1989;46:89-99. (Pubitemid 19038412)
27. Du L, Bakish D, Ravindran AV, et al. Does fluoxetine influence major depression by modifying five-factor personality traits? J Affect Disord. 2002;71:235-241.
28. Bagby RM, Joffe RT, Parker JDA, et al. Major depression and the five-factor model of personality. J Pers Disord. 1995;9:224-234.
29. Weissman MM, Prusoff BA, Klerman GL. Personality and the prediction of long-term outcome of depression. Am J Psychiatry. 1978;135:797-800. (Pubitemid 8371293)
30. Hirschfeld RM, Klerman GL, Andreasen NC, et al. Psycho-social predictors of chronicity in depressed patients. Br J Psychiatry. 1986;148:648-654. (Pubitemid 16056785)
31. Quilty LC, De Fruyt F, Rolland JP, et al. Dimensional personality traits and treatment outcome in patients with major depressive disorder. J Affect Disord. 2008;108:241-250.
32. Costa PT Jr, Bagby RM, Herbst JH, et al. Personality self-reports are concurrently reliable and valid during acute depressive episodes. J Affect Disord. 2005;89:45-55. (Pubitemid 41740832)
33. Bagby RM, Levitan RD, Kennedy SH, et al. Selective alteration of personality in response to noradrenergic and serotonergic antidepressant medication in depressed sample: evidence of non-specificity. Psychiatry Res. 1999;86:211-216. (Pubitemid 29393043)
34. Quilty LC, Meusel LA, Bagby RM. Neuroticism as a mediator of treatment response to SSRIs in major depressive disorder. J Affect Disord. 2008;111:67-73.
35. Kleindienst N, Engel RR, Greil W. Psychosocial and demographic factors associated with response to prophylactic lithium: a systematic review for bipolar disorders. Psychol Med. 2005;35:1685-1694. (Pubitemid 41672347)
36. Costa PT Jr, McCrae RR. Domains and facets: hierarchical personality assessment using the revised NEO personality inventory. J Pers Assess. 1995;64:21-50.
37. Costa PT Jr, McCrae RR. NEO PI-R professional manual. Lutz, FL: Psychological Assessment Resources, Inc.; 1992.
38. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382-389. (Pubitemid 9136500)
39. Kobak KA, Williams JB, Jeglic E, et al. Face-to-face versus remote administration of the Montgomery- Asberg Depression Rating Scale using videoconference and telephone. Depress Anxiety. 2008;25:913-919.
40. Hermens ML, Adèr HJ, van Hout HP, et al. Administering the MADRS by telephone or face-to-face: a validity study. Ann Gen Psychiatry. 2006;5:3.
41. Rose HG, Oklander M. Improved procedure for the extraction of lipids from human erythrocytes. J Lipid Res. 1965;6:428-431.
42. Spector AA, Ashbrook JD, Santos EC, et al. Quantitative analysis of uptake of free fatty acid by mammalian cells: lauric acid and human erythrocytes. J Lipid Res. 1972;13:445-451.
43. Morrison WR, Smith LM. Preparation of fatty acid methyl esters and dimethylacetals from lipids with boron fluoride-methanol. J Lipid Res. 1964;5:600-608.
44. Martin DD, Robbins ME, Spector AA, et al. The fatty acid composition of human gliomas differs from that found in nonmalignant brain tissue. Lipids. 1996;31:1283-1288. (Pubitemid 26425024)
45. Williard DE, Harmon SD, Kaduce TL, et al. Docosahexaenoic acid synthesis from n-3 polyunsaturated fatty acids in differentiated rat brain astrocytes. J Lipid Res. 2001;42:1368-1376. (Pubitemid 34007666)
46. Block RC, Harris WS, Reid KJ, et al. Omega-6 and trans fatty acids in blood cell membranes: a risk factor for acute coronary syndromes? Am Heart J. 2008;156: 1117-1123.
47. Wennberg M, Bergdahl IA, Stegmayr B, et al. Fish intake, mercury, long-chain n-3 polyunsaturated fatty acids and risk of stroke in northern Sweden. Br J Nutr. 2007;98:1038-1045. (Pubitemid 47543464)
48. Broadfield EC, McKeever TM, Whitehurst A, et al. A case-control study of dietary and erythrocyte membrane fatty acids in asthma. Clin Exp Allergy. 2004;34:1232-1236. (Pubitemid 39093062)
49. Iso H, Sato S, Umemura U, et al. Linoleic acid, other fatty acids, and the risk of stroke. Stroke. 2002;33:2086-2093. (Pubitemid 34840073)
50. Levant B, Ozias MK, Davis PF, et al. Decreased brain docosahexaenoic acid content produces neurobiological effects associated with depression: interactions with reproductive status in female rats. Psychoneuroendocrinology. 2008;33:1279-1292.
51. Akiskal HS. Toward a definition of generalized anxiety disorder as an anxious temperament type. Acta Psychiatr Scand Suppl. 1998;393:66-73. (Pubitemid 28428195)
52. Bruijn JA, Moleman P, van den Broek WW, et al. Trait anxiety and the effect of a single high dose of diazepam in unipolar depression. J Psychiatr Res. 2001;35:331-337. (Pubitemid 33000470)
53. Fava M, Rush AJ, Alpert JE, et al. Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D report. Am J Psychiatry. 2008;165:342-351. (Pubitemid 351704490)
54. Fava M, Rush AJ, Alpert JE, et al. What clinical and symptom features and comorbid disorders characterize outpatients with anxious major depressive disorder: a replication and extension. Can J Psychiatry. 2006;51:823-835. (Pubitemid 46354060)
55. Frokjaer VG, Mortensen EL, Nielsen FA, et al. Frontolimbic serotonin 2A receptor binding in healthy subjects is associated with personality risk factors for affective disorder. Biol Psychiatry. 2008;63:569-576. (Pubitemid 351273195)
56. Takano A, Arakawa R, Hayashi M, et al. Relationship between neuroticism personality trait and serotonin transporter binding. Biol Psychiatry. 2007;62:588-592. (Pubitemid 47314374)
57. Fiedorowicz JG, Moser DJ, Hynes SM, et al. LA allelic heterozygosity of the 5HTTLPR polymorphism is associated with higher cognitive function and lower interpersonal sensitivity. Psychiatr Genet. 2007;17:3-4. (Pubitemid 44953336)
58. Gonda X, Rihmer Z, Zsombok T, et al. The 5HTTLPR polymorphism of the serotonin transporter gene is associated with affective temperaments as measured by TEMPS-A. J Affect Disord. 2006;91:125-131.
59. Smeraldi E, Zanardi R, Benedetti F, et al. Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine. Mol Psychiatry. 1998;3:508-511. (Pubitemid 28515526)
60. Pohl R, Yeragani VK, Balon R, et al. The jitteriness syndrome in panic disorder patients treated with antidepressants. J Clin Psychiatry. 1988;49:100-104. (Pubitemid 18091342)
61. Burke WJ, Gergel I, Bose A. Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients. J Clin Psychiatry. 2002;63:331-336. (Pubitemid 34456361)